STOCK TITAN

[Form 4] Relmada Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Relmada Therapeutics, Inc. (RLMD) – Form 4 insider filing: The company’s Chief Financial Officer, Maged Shenouda, was granted stock options for 600,000 common shares on 06/26/2025. The options carry an exercise price of $0.67 per share and will vest in 16 equal quarterly installments beginning 09/26/2025, fully vesting by 06/26/2035. Following the grant, Shenouda beneficially owns 600,000 derivative securities, reported as direct ownership. No shares were purchased or sold in the open market; this filing records an equity incentive award, aligning executive compensation with future shareholder value.

Relmada Therapeutics, Inc. (RLMD) – Comunicazione interna Form 4: Il Chief Financial Officer dell'azienda, Maged Shenouda, ha ricevuto opzioni su azioni per 600.000 azioni ordinarie il 26/06/2025. Le opzioni prevedono un prezzo di esercizio di 0,67 $ per azione e si matureranno in 16 rate trimestrali uguali a partire dal 26/09/2025, con maturazione completa entro il 26/06/2035. A seguito della concessione, Shenouda detiene beneficiariamente 600.000 titoli derivati, riportati come proprietà diretta. Non sono state acquistate o vendute azioni sul mercato aperto; questa comunicazione registra un premio azionario incentivante, allineando la remunerazione degli executive al valore futuro per gli azionisti.

Relmada Therapeutics, Inc. (RLMD) – Presentación interna Formulario 4: El Director Financiero de la empresa, Maged Shenouda, recibió opciones sobre 600.000 acciones comunes el 26/06/2025. Las opciones tienen un precio de ejercicio de $0.67 por acción y se otorgarán en 16 cuotas trimestrales iguales comenzando el 26/09/2025, con otorgamiento completo para el 26/06/2035. Tras la concesión, Shenouda posee beneficiosamente 600.000 valores derivados, reportados como propiedad directa. No se compraron ni vendieron acciones en el mercado abierto; esta presentación registra un premio de incentivos en acciones, alineando la compensación ejecutiva con el valor futuro para los accionistas.

Relmada Therapeutics, Inc. (RLMD) – 내부자 신고서 Form 4: 회사의 최고재무책임자(CFO) Maged Shenouda가 2025년 6월 26일에 600,000주 보통주에 대한 스톡옵션을 부여받았습니다. 이 옵션은 주당 행사가격이 $0.67이며 2025년 9월 26일부터 시작하여 16회에 걸쳐 동일한 분기별 할부로 권리가 확정되며, 2035년 6월 26일까지 완전히 권리가 확정됩니다. 부여 후 Shenouda는 직접 소유로 보고된 600,000개의 파생 증권을 실질 소유하고 있습니다. 공개 시장에서 주식을 매수하거나 매도하지 않았으며, 이 신고는 임원 보상과 미래 주주 가치를 연계하는 주식 인센티브 수여를 기록한 것입니다.

Relmada Therapeutics, Inc. (RLMD) – Déclaration d’initié Formulaire 4 : Le directeur financier de la société, Maged Shenouda, s’est vu attribuer des options d’achat portant sur 600 000 actions ordinaires le 26/06/2025. Les options ont un prix d’exercice de 0,67 $ par action et seront acquises en 16 versements trimestriels égaux à partir du 26/09/2025, avec une acquisition complète au 26/06/2035. Suite à cette attribution, Shenouda détient de manière bénéficiaire 600 000 titres dérivés, déclarés comme propriété directe. Aucune action n’a été achetée ou vendue sur le marché ouvert ; cette déclaration enregistre une attribution d’incitation en actions, alignant la rémunération des dirigeants sur la valeur future pour les actionnaires.

Relmada Therapeutics, Inc. (RLMD) – Insider-Meldung Form 4: Der Chief Financial Officer des Unternehmens, Maged Shenouda, erhielt am 26.06.2025 Aktienoptionen für 600.000 Stammaktien. Die Optionen haben einen Ausübungspreis von 0,67 $ pro Aktie und werden in 16 gleichen vierteljährlichen Tranchen ab dem 26.09.2025 ausgeübt, mit vollständiger Vesting bis zum 26.06.2035. Nach der Gewährung besitzt Shenouda wirtschaftlich 600.000 derivative Wertpapiere, die als direkter Besitz gemeldet sind. Es wurden keine Aktien am offenen Markt gekauft oder verkauft; diese Meldung dokumentiert eine Aktienanreizprämie, die die Vergütung der Führungskräfte mit dem zukünftigen Aktionärswert in Einklang bringt.

Positive
  • Long-term vesting schedule promotes executive retention and aligns CFO incentives with shareholder value.
  • No insider selling; the filing reflects an option grant rather than disposal of existing shares.
Negative
  • Potential dilution if all 600,000 options are exercised, increasing outstanding share count.
  • Strike price of $0.67 may signal low current valuation, highlighting execution risk for value realization.

Insights

TL;DR: Routine option grant; modest positive alignment, minimal short-term impact.

The 600,000-share option award strengthens management retention and incentive alignment, especially given RLMD’s depressed $0.67 strike price. However, the grant represents potential dilution only if exercised and is standard for a C-suite hire/retention, so market impact should be neutral to mildly positive. No immediate cash outflow or insider selling occurred, and vesting over four years promotes long-term commitment. Investors should monitor total option overhang but need not expect short-term price movement based solely on this filing.

Relmada Therapeutics, Inc. (RLMD) – Comunicazione interna Form 4: Il Chief Financial Officer dell'azienda, Maged Shenouda, ha ricevuto opzioni su azioni per 600.000 azioni ordinarie il 26/06/2025. Le opzioni prevedono un prezzo di esercizio di 0,67 $ per azione e si matureranno in 16 rate trimestrali uguali a partire dal 26/09/2025, con maturazione completa entro il 26/06/2035. A seguito della concessione, Shenouda detiene beneficiariamente 600.000 titoli derivati, riportati come proprietà diretta. Non sono state acquistate o vendute azioni sul mercato aperto; questa comunicazione registra un premio azionario incentivante, allineando la remunerazione degli executive al valore futuro per gli azionisti.

Relmada Therapeutics, Inc. (RLMD) – Presentación interna Formulario 4: El Director Financiero de la empresa, Maged Shenouda, recibió opciones sobre 600.000 acciones comunes el 26/06/2025. Las opciones tienen un precio de ejercicio de $0.67 por acción y se otorgarán en 16 cuotas trimestrales iguales comenzando el 26/09/2025, con otorgamiento completo para el 26/06/2035. Tras la concesión, Shenouda posee beneficiosamente 600.000 valores derivados, reportados como propiedad directa. No se compraron ni vendieron acciones en el mercado abierto; esta presentación registra un premio de incentivos en acciones, alineando la compensación ejecutiva con el valor futuro para los accionistas.

Relmada Therapeutics, Inc. (RLMD) – 내부자 신고서 Form 4: 회사의 최고재무책임자(CFO) Maged Shenouda가 2025년 6월 26일에 600,000주 보통주에 대한 스톡옵션을 부여받았습니다. 이 옵션은 주당 행사가격이 $0.67이며 2025년 9월 26일부터 시작하여 16회에 걸쳐 동일한 분기별 할부로 권리가 확정되며, 2035년 6월 26일까지 완전히 권리가 확정됩니다. 부여 후 Shenouda는 직접 소유로 보고된 600,000개의 파생 증권을 실질 소유하고 있습니다. 공개 시장에서 주식을 매수하거나 매도하지 않았으며, 이 신고는 임원 보상과 미래 주주 가치를 연계하는 주식 인센티브 수여를 기록한 것입니다.

Relmada Therapeutics, Inc. (RLMD) – Déclaration d’initié Formulaire 4 : Le directeur financier de la société, Maged Shenouda, s’est vu attribuer des options d’achat portant sur 600 000 actions ordinaires le 26/06/2025. Les options ont un prix d’exercice de 0,67 $ par action et seront acquises en 16 versements trimestriels égaux à partir du 26/09/2025, avec une acquisition complète au 26/06/2035. Suite à cette attribution, Shenouda détient de manière bénéficiaire 600 000 titres dérivés, déclarés comme propriété directe. Aucune action n’a été achetée ou vendue sur le marché ouvert ; cette déclaration enregistre une attribution d’incitation en actions, alignant la rémunération des dirigeants sur la valeur future pour les actionnaires.

Relmada Therapeutics, Inc. (RLMD) – Insider-Meldung Form 4: Der Chief Financial Officer des Unternehmens, Maged Shenouda, erhielt am 26.06.2025 Aktienoptionen für 600.000 Stammaktien. Die Optionen haben einen Ausübungspreis von 0,67 $ pro Aktie und werden in 16 gleichen vierteljährlichen Tranchen ab dem 26.09.2025 ausgeübt, mit vollständiger Vesting bis zum 26.06.2035. Nach der Gewährung besitzt Shenouda wirtschaftlich 600.000 derivative Wertpapiere, die als direkter Besitz gemeldet sind. Es wurden keine Aktien am offenen Markt gekauft oder verkauft; diese Meldung dokumentiert eine Aktienanreizprämie, die die Vergütung der Führungskräfte mit dem zukünftigen Aktionärswert in Einklang bringt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Shenouda Maged

(Last) (First) (Middle)
C/O RELMADA THERAPEUTICS, INC.
2222 PONCE DE LEON BLVD, 3RD FLOOR

(Street)
CORAL GABLES, FL 33134

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RELMADA THERAPEUTICS, INC. [ RLMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $0.67 06/26/2025 A 600,000 09/26/2025(1) 06/26/2035 Common Stock 600,000 $0 600,000 D
Explanation of Responses:
1. The options vest in 16 equal quarterly installments commencing on September 26, 2025.
/s/ Maged Shenouda 06/30/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider involved in RLMD's latest Form 4 filing?

The filing involves Maged Shenouda, Chief Financial Officer of Relmada Therapeutics.

How many options were granted to RLMD's CFO?

He received 600,000 stock options for Relmada’s common stock.

What is the exercise price of the newly granted RLMD options?

The options have an exercise price of $0.67 per share.

When do the RLMD options vest?

They vest in 16 equal quarterly installments starting 09/26/2025 and fully vest by 06/26/2035.

Did RLMD's CFO buy or sell any shares in this filing?

No. The Form 4 only reports an option grant; there was no purchase or sale of common shares.
Relmada Therapeutics Inc

NASDAQ:RLMD

RLMD Rankings

RLMD Latest News

RLMD Latest SEC Filings

RLMD Stock Data

22.34M
26.56M
8.04%
29.85%
4.19%
Biotechnology
Pharmaceutical Preparations
Link
United States
CORAL GABLES